AANP Adult Gerontology Primary Care Nurse Practiotioner Practice

Incretin mimetics, also known as GLP-1 receptor agonists, primarily function by delaying gastric emptying. This mechanism enhances the feeling of fullness (satiety) after meals, which can aid in weight management and improve glycemic control in individuals with type 2 diabetes. By slowing the passage of food from the stomach to the intestines, these medications not only help regulate blood sugar levels more effectively but also contribute to better postprandial (after eating) glucose control. The other options do not align with the primary actions of incretin mimetics. Incretin mimetics do not inhibit insulin secretion; rather, they stimulate insulin secretion in response to increased blood glucose levels. They also do not increase glucagon secretion; instead, they promote a reduction in glucagon levels postprandially, which helps to lower blood sugar levels. Lastly, they do not stimulate glucose production in the liver; rather, they work to suppress hepatic glucose production, further contributing to blood glucose regulation. Therefore, the correct understanding of incretin mimetics is that they primarily delay stomach emptying, which aids in controlling blood sugar and improving fullness.